A Phase 3 interventional study of Megestrol acetate concentrated suspension 110 mg/mL and Megestrol acetate concentrated suspension 60 mg/mL in Anorexia, Cachexia and Weight Loss, sponsored by Par Pharmaceutical, Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-02.
Sponsored by Par Pharmaceutical, Inc. (part of Par Health) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Megestrol Acetate in Anorexia — 1 open to participants now, 1 under way, none of them phase 3. Megestrol Acetate · Anorexia.
Among the 12 studies testing Megestrol Acetate in Anorexia, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2006, is one of 6 in phase 3, and was the 7th registered.
163 studies on the registry are indexed under Anorexia; 25 are open to participants now.
Browse Anorexia studies →1 of the 12 studies testing Megestrol Acetate in Anorexia is open now, in 1 country. Recruiting first, the newest first:
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →
Of the 12 Anorexia studies recruiting now, 6 (50%) set no upper age limit and 6 (50%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2006.
This study's enrollment of 4 is below the median of 49 across 125 interventional studies indexed under Anorexia.
Median enrollment 19 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 8 most frequent:
This study is registered under Par Pharmaceutical, Inc., one of the names counted as Par Health. Under that name alone:
Par Pharmaceutical, Inc. is the lead sponsor of 36 studies on the registry; none are open to participants now.
Par Health has 2 studies filed under Anorexia — fewer than ten, so there is no comparison to draw.
1 of the studies testing Megestrol Acetate in Anorexia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565415Nanfang Hospital, Southern Medical UniversityNanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing Megestrol Acetate in Anorexia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the effect of megestrol acetate concentrated suspension and placebo on caloric intake in patients with cancer-associated anorexia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Megestrol acetate concentrated suspension 110 mg/mL
Drug: Megestrol acetate concentrated suspension 110 mg/mL
Megestrol acetate concentrated suspension 60 mg/mL
Drug: Megestrol acetate concentrated suspension 60 mg/mL
Drug: Placebo
Drug page: Megestrol Acetate
Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Also known as: Megace ES
Drug page: Megestrol Acetate
Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
Also known as: Megace ES
Placebo oral suspension, 5 mL once daily
Average Daily Caloric Intake Over the Course of the 8-week Double-blind Phase
The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value.
Time frame: 8 weeks
Change in Weight Over the Course of the 8-week Double-blind Phase
Time frame: Baseline, Week 1, 2, 3, 4, 6, and 8
Changes in Body Composition as Measured by Bioelectric Impedance Analysis (BIA) at Week 4 and Week 8 Relative to Baseline
Time frame: Baseline, Week 4 and Week 8
Change in Appetite Over the 8-week Double-blind Phase as Measured by a VAS Appetite Scale
Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food
Time frame: Baseline, Weeks 1, 2, 3, 4, 6 and 8
| Milestone | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | OL MA-CS 550 mg/Day |
|---|---|---|---|---|
| Started | 2 | 0 | 2 | 0 |
| Completed | 0 | 0 | 1 | 0 |
| Not completed | 2 | 0 | 1 | 0 |
| Withdrew: Study discontinued | 2 | 0 | 1 | 0 |
| Milestone | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | OL MA-CS 550 mg/Day |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 1 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Study discontinued | 0 | 0 | 0 | 1 |
The Nutrition Data System for Research (NDSR) was used to determine nutrient and caloric value for foods and beverages consumed and recorded by subjects over a 3-day assessment period prior to each visit. Total number of calories consumed during each 3-day assessment was averaged over available values to determine the week's daily caloric intake value.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Subjects marked 6 items on a visual analog scale (VAS) appetite scale including feeling not hungry to hungry, not nauseated to nauseated, empty to full, not satiated to satiated; weak to strong desire to eat; and ability to eat none to a large amount of food
No measurements were reported for this outcome.
Collected over Approximately 98 days (from informed consent through 7 days following the last dose of study drug or up until the last protocol-specified study visit, whichever occurred later). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB MA-CS 550 mg/Day | — | 0/2 (0%) | 1/2 (50%) |
| DB MA-CS 300 mg/Day | — | — | — |
| DB Placebo | — | 1/2 (50%) | 2/2 (100%) |
| OL MA-CS 550 mg/Day | — | 1/1 (100%) | 1/1 (100%) |
| Event | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | OL MA-CS 550 mg/Day |
|---|---|---|---|---|
| Accident at homeInjury, poisoning and procedural complications | 0/2 | — | 0/2 | 1/1 |
| Rib fractureInjury, poisoning and procedural complications | 0/2 | — | 0/2 | 1/1 |
| ConcussionInjury, poisoning and procedural complications | 0/2 | — | 0/2 | 1/1 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/2 | — | 1/2 | 0/1 |
| Event | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | OL MA-CS 550 mg/Day |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 0/2 | — | 1/2 | 1/1 |
| Chest painGeneral disorders | 0/2 | — | 1/2 | 1/1 |
| VomitingGastrointestinal disorders | 0/2 | — | 1/2 | 1/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/2 | — | 1/2 | 0/1 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/2 | — | 1/2 | 0/1 |
| Abdominal painGastrointestinal disorders | 1/2 | — | 0/2 | 0/1 |
| NauseaGastrointestinal disorders | 1/2 | — | 0/2 | 0/1 |
| FatigueGeneral disorders | 1/2 | — | 0/2 | 0/1 |
All subjects who received at least 1 dose of study medication and who had at least 1 on-therapy safety assessment
| Age, Categorical(participants) | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | — | 0 | 0 |
| Between 18 and 65 years | 1 | — | 0 | 1 |
| >=65 years | 1 | — | 2 | 3 |
| Gender(participants) | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | Total |
|---|---|---|---|---|
| Female | 1 | — | 0 | 1 |
| Male | 1 | — | 2 | 3 |
| Ethnicity (NIH/OMB)(participants) | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | — | 0 | 0 |
| Not Hispanic or Latino | 2 | — | 2 | 4 |
| Unknown or Not Reported | 0 | — | 0 | 0 |
| Race (NIH/OMB)(participants) | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | — | 0 | 0 |
| Asian | 0 | — | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | — | 0 | 0 |
| Black or African American | 0 | — | 0 | 0 |
| White | 2 | — | 1 | 3 |
| More than one race | 0 | — | 0 | 0 |
| Unknown or Not Reported | 0 | — | 0 | 0 |
| Region of Enrollment(participants) | DB MA-CS 550 mg/Day | DB MA-CS 300 mg/Day | DB Placebo | Total |
|---|---|---|---|---|
| United States | 2 | — | 2 | 4 |
The record gives a start of Jun 2006, a primary completion of Sep 2006 and a completion of Sep 2006. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 9 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Megestrol Acetate